ATNF 180 Life Sciences Corp. Stock Quote

ATNF [NASD]

Index	-	P/E	-	EPS (ttm)	-0.95	Insider Own	12.30%	Shs Outstand	34.13M	Perf Week	-1.54%
Market Cap	87.37M	Forward P/E	-	EPS next Y	-0.55	Insider Trans	3.00%	Shs Float	22.73M	Perf Month	-32.10%
Income	-24.40M	PEG	-	EPS next Q	-0.13	Inst Own	7.70%	Short Float	6.95%	Perf Quarter	-50.58%
Sales	-	P/S	-	EPS this Y	-	Inst Trans	-0.04%	Short Ratio	1.58	Perf Half Y	-63.79%
Book/sh	1.13	P/B	2.27	EPS next Y	32.10%	ROA	-41.10%	Target Price	11.00	Perf Year	-26.44%
Cash/sh	0.34	P/C	7.47	EPS next 5Y	-	ROE	-105.00%	52W Range	2.25 - 13.05	Perf YTD	-34.36%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-80.38%	Beta	-0.32
Dividend %	-	Quick Ratio	0.60	Sales past 5Y	-	Gross Margin	-	52W Low	13.78%	ATR	0.30
Employees	6	Current Ratio	0.60	Sales Q/Q	-	Oper. Margin	-	RSI (14)	31.69	Volatility	10.32% 9.57%
Optionable	Yes	Debt/Eq	0.01	EPS Q/Q	184.90%	Profit Margin	-	Rel Volume	0.40	Prev Close	2.66
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	997.02K	Price	2.56
Recom	2.00	SMA20	-19.96%	SMA50	-32.80%	SMA200	-61.41%	Volume	402,356	Change	-3.76%

Sep-15-21

Initiated

Maxim Group

Buy

$11

Dec-28-21 11:00AM	180 Life Sciences Corp. To Participate in the Biotech Showcase 2022 Virtual Conference To be Held January 10-12, 2022 GlobeNewswire -5.75%
Dec-15-21 08:15AM	180 Life Sciences Corp. Enters into a License Agreement with University of Oxford for Regenerative Molecule HMGB1 for Liver Diseases GlobeNewswire
Dec-12-21 06:06AM	Insider Buying: The 180 Life Sciences Corp. (NASDAQ:ATNF) Lead Independent Director Just Bought 328% More Shares Simply Wall St.
Dec-10-21 05:15PM	180 Life Sciences Corp (ATNF) CEO James N. Woody Bought $53,375 of Shares GuruFocus.com
Dec-06-21 08:15AM	180 Life Sciences Provides Follow-Up Information on Oxford University and the Companys Successful Dupuytrens Phase 2b Clinical Trial Results GlobeNewswire +7.95%
Dec-01-21 02:45PM	180 Life Sciences Corp. Co-Founder Prof. Jagdeep Nanchahal Presents Keynote Address at the 2021 International Dupuytren Symposium, Including Top Line Data From the Phase 2b Clinical Trial GlobeNewswire -20.85%
02:26PM	180 Life Sciences: Positive Data From Dupuytrens Disease Study Could Be a Big Catalyst, Says Analyst TipRanks
Nov-22-21 08:30AM	180 Life Sciences Corp. Expands Patent Portfolio GlobeNewswire
Nov-18-21 08:15AM	180 Life Sciences Corp. Co-Founder Prof. Jagdeep Nanchahal to Present a Keynote Address at the 2021 International Dupuytren Symposium GlobeNewswire +9.86%
Nov-03-21 12:06PM	180 Life Sciences Corp. Names Quan A. Vu Chief Operating Officer/Chief Business Officer GlobeNewswire
Oct-26-21 08:30AM	180 Life Sciences Corp. Publishes Pre-Clinical Study Report on the Effects of CBG Derivatives on Pain, Inflammation and Obesity in The Journal Molecules GlobeNewswire
Sep-30-21 08:30AM	180 Life Sciences Corp. Continues To Expand Intellectual Property Portfolio GlobeNewswire +5.66%
Sep-20-21 08:00AM	Celltrion Healthcare and 180 Life Sciences Enter Into Memorandum of Understanding for a Supply Agreement for the Ongoing Supply of Drug for Anti-TNF Product Trials for Novel Indications GlobeNewswire -6.29%
Aug-30-21 08:30AM	180 Life Sciences Corp. CEO James Woody, MD, PhD Issues Letter to Stockholders GlobeNewswire
Aug-24-21 08:30AM	180 Life Sciences Corp. Announces Closing of $15.0 Million Private Placement GlobeNewswire
Aug-19-21 09:00AM	180 Life Sciences Corp. Announces $15.0 Million Private Placement GlobeNewswire -25.73%
08:10AM	Is 180 Life Sciences Corp.'s (NASDAQ:ATNF) Shareholder Ownership Skewed Towards Insiders? Simply Wall St.
Aug-02-21 08:00AM	Chairman of the 180 Life Sciences Clinical Advisory Board, Professor Jagdeep Nanchahal, has Been Invited To Present a Keynote Talk at the British Society for Surgery of the Hand (BSSH) at the Autumn Scientific Meeting in Oxford UK on September 9, 2021 GlobeNewswire
Jul-29-21 08:00AM	180 Life Sciences to Participate in Fireside Chat at BTIG Virtual Biotechnology Conference GlobeNewswire
Jul-28-21 08:15AM	180 Life Sciences Announces Selection of Lead Synthetic CBD Analogue GlobeNewswire
Jul-20-21 08:00AM	180 Life Sciences Regains Nasdaq Compliance Under Listing Rule 5250(c)(1) GlobeNewswire
Jul-12-21 09:51AM	180 Life Sciences Regains Nasdaq Compliance for Listing Rules 5605(b)(1) and 5605(c)(2) GlobeNewswire +9.75%
Jul-07-21 08:00AM	180 Life Sciences Expands Scientific Fibrosis Platform with Collagen VI as a Driver and Disease Biomarker in Human Fibrosis Published in the FEBS Journal GlobeNewswire
Jun-28-21 08:15AM	180 Life Sciences Joins Russell Microcap® Index GlobeNewswire
08:00AM	180 Life Sciences Files Plan with Nasdaq Related to Delayed Quarterly Report on Form 10-Q and Form 10-K GlobeNewswire
Jun-10-21 09:12AM	180 Life Sciences Corp. Announces the Appointment of Pamela Marrone, PhD and Frank Knuettel II, MBA to Board of Directors GlobeNewswire
Jun-01-21 08:00AM	180 Life Sciences Corp. to Present at LD Micro Invitational XI GlobeNewswire +8.90%
May-28-21 08:00AM	180 Life Sciences Corp. Announces the Appointment of Russell T. Ray, MBA and Teresa DeLuca MD, MBA to Board of Directors GlobeNewswire +7.96%
May-21-21 04:45PM	180 Life Sciences Corp. Receives Expected Notification From Nasdaq Related To Delayed Quarterly Report on Form 10-Q GlobeNewswire +10.61%
Apr-20-21 08:00AM	180 Life Sciences Corp. Announces Collection of All Patient Data for Phase 2b Dupuytrens Disease Trial GlobeNewswire
Apr-19-21 05:00PM	180 Life Sciences Corp. Receives Expected Notification From Nasdaq Related To Delayed Annual Report on Form 10-K GlobeNewswire -16.53%
Apr-14-21 08:15AM	180 Life Sciences Corp. Congratulates Dr. Lynn Williams on International Dupuytren Award 2021 GlobeNewswire
Mar-26-21 08:30AM	180 Life Sciences Corp. (NASDAQ: ATNF) Recognized R&D Pioneers in Anti-Inflammatory Therapeutics GlobeNewswire +18.57%
Mar-25-21 08:30AM	180 Life Sciences Corp. (NASDAQ: ATNF) in Hot Pursuit of New Anti-Inflammatory Blockbusters GlobeNewswire +13.65%
Mar-24-21 08:30AM	180 Life Sciences Corp. CEO James Woody, MD, PhD Issues Letter to Stockholders GlobeNewswire
Mar-08-21 01:30PM	180 Life Sciences Corp. to Present at Inaugural Emerging Growth Virtual Conference, presented by M Vest LLC and Maxim Group LLC GlobeNewswire +5.46%
Feb-24-21 04:00PM	180 Life Sciences Corp. Announces Closing of $11.7 Million Private Placement GlobeNewswire +11.06%
Feb-19-21 09:00AM	180 Life Sciences Corp. Announces $11.7 Million Private Placement GlobeNewswire -13.46%
Feb-17-21 12:00AM	Do Insiders Own Lots Of Shares In 180 Life Sciences Corp. (NASDAQ:ATNF)? Simply Wall St. -5.45%
Jan-11-21 08:00AM	180 Life Sciences Corp. to Present at the Biotech Showcase(TM) Digital 2021 Conference Newsfile +5.06%
Jan-05-21 02:50PM	180 Life Sciences Corp. to Present at the H.C. Wainwright Bioconnect 2021 Conference GlobeNewswire +7.17%
Dec-03-20 11:08AM	180 Life Sciences Corp. to Present at the 13th Annual LD Micro Main Event Conference on Tuesday, December 15th at 1:40 PM EST GlobeNewswire
Nov-24-20 10:00AM	180 Life Sciences Corp. to Ring Nasdaq Opening Bell on November 27, 2020 GlobeNewswire -6.93%
Nov-23-20 08:30AM	180 Life Sciences Corp. Continues to Expand Intellectual Property Portfolio With Additional Patent Grants GlobeNewswire +17.44%
Nov-17-20 08:00AM	180 Life Sciences Corp. CEO James Woody, MD, PhD Issues Letter to Stockholders GlobeNewswire
Nov-10-20 11:46AM	180 Life Sciences Announces Completion of Transaction with KBLM Merger Corp IV GlobeNewswire -6.47%

180 Life Sciences Corp., a clinical-stage biotechnology company, engages in the development of novel drugs for unmet medical needs in chronic pain, inflammation, inflammatory diseases, and fibrosis. Its product development platforms in Phase IIb/III clinical trials include Fibrosis and anti-tumour necrosis factor (Anti-TNF) platform, which focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are man-made derivatives of CBD; and a7nAChR platform, which focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Vu Quan Anh	COO / Chief Business Officer	Dec 16	Buy	3.98	8,000	31,840	20,500	Dec 16 05:00 PM
Pamir Ozan	Interim CFO	Dec 10	Buy	3.87	3,800	14,706	76,408	Dec 13 08:31 AM
Marrone Pamela G	Director	Dec 10	Buy	4.10	1,000	4,100	1,000	Dec 10 06:39 PM
Vu Quan Anh	COO / Chief Business Officer	Dec 10	Buy	3.90	4,500	17,550	12,500	Dec 10 06:04 PM
McGovern Jr. Donald A.	Director	Dec 09	Buy	4.13	25,000	103,250	32,628	Dec 09 09:58 PM
Woody James N.	Chief Executive Officer	Dec 09	Buy	4.27	12,500	53,375	37,752	Dec 10 08:24 AM
STEINMAN LAWRENCE	Director	Dec 09	Buy	4.27	5,000	21,350	602,574	Dec 10 08:22 AM
Feldmann Marc	Director	Dec 09	Buy	4.07	50,000	203,500	2,809,930	Dec 13 04:18 PM
DeLuca Teresa	Director	Dec 09	Buy	3.97	7,500	29,800	2,500	Dec 13 08:35 AM
DeLuca Teresa	Director	Dec 09	Buy	4.00	5,000	20,000	5,000	Dec 13 08:35 AM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience